Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

Epstein–Barr virus-associated diseases are important global health concerns. As a group I carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial- and lymphatic-originated tumors. Moreover, EBV plays an etiological and pathogenic role in a number of non-neoplastic diseases,...

Full description

Saved in:
Bibliographic Details
Published in:Signal transduction and targeted therapy 2021-01, Vol.6 (1), p.15-33, Article 15
Main Authors: Cao, Ya, Xie, Longlong, Shi, Feng, Tang, Min, Li, Yueshuo, Hu, Jianmin, Zhao, Lin, Zhao, Luqing, Yu, Xinfang, Luo, Xiangjian, Liao, Weihua, Bode, Ann M.
Format: Article
Language:English
Subjects:
631/67/1059
631/67/2327
Autoimmune Diseases - genetics
Autoimmune Diseases - immunology
Autoimmune Diseases - pathology
Cancer Research
Cell Biology
Chemoradiotherapy
DNA methylation
Epstein-Barr virus
Epstein-Barr Virus Infections - genetics
Epstein-Barr Virus Infections - immunology
Epstein-Barr Virus Infections - pathology
Herpesvirus 4, Human - genetics
Herpesvirus 4, Human - immunology
Humans
Internal Medicine
Medicine
Medicine & Public Health
Neoplasms
Oncology
Pathology
Review
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Epstein–Barr virus-associated diseases are important global health concerns. As a group I carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial- and lymphatic-originated tumors. Moreover, EBV plays an etiological and pathogenic role in a number of non-neoplastic diseases, and is even involved in multiple autoimmune diseases (SADs). In this review, we summarize and discuss some recent exciting discoveries in EBV research area, which including DNA methylation alterations, metabolic reprogramming, the changes of mitochondria and ubiquitin-proteasome system (UPS), oxidative stress and EBV lytic reactivation, variations in non-coding RNA (ncRNA), radiochemotherapy and immunotherapy. Understanding and learning from this advancement will further confirm the far-reaching and future value of therapeutic strategies in EBV-associated diseases.
ISSN:2059-3635
2095-9907
2059-3635
DOI:10.1038/s41392-020-00376-4